Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis-0

Alist. Rx = Prescribed treatment. * seen by an ID during a period of 5 years. Not included in study: -Patients who did not require antibiotic. -Former IVDU who had stopped using narcotics at least two years prior to their admittance to the hospital and were not participating in an opioid maintenance program p = 0.03 (Rx according to guidelines vs. others)<p><b>Copyright information:</b></p><p>Taken from "Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis"</p><p>http://www.biomedcentral.com/1471-2334/8/42</p><p>BMC Infectious Diseases 2008;8():42-42.</p><p>Published online 3 Apr 2008</p><p>PMCID:PMC2323004.</p><p></p

Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis-1

Alist. Rx = Prescribed treatment. * seen by an ID during a period of 5 years. Not included in study: -Patients who did not require antibiotic. -Former IVDU who had stopped using narcotics at least two years prior to their admittance to the hospital and were not participating in an opioid maintenance program p = 0.03 (Rx according to guidelines vs. others)<p><b>Copyright information:</b></p><p>Taken from "Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis"</p><p>http://www.biomedcentral.com/1471-2334/8/42</p><p>BMC Infectious Diseases 2008;8():42-42.</p><p>Published online 3 Apr 2008</p><p>PMCID:PMC2323004.</p><p></p

Comparison of therapies for prosthetic vascular graft infections with respect to the location of the graft.^*

<p>PVGI  =  prosthetic vascular graft infection; IQR  =  interquartile range</p><p>*Percentages, IQR values, and ranges indicate relationship to the total number of patients within each respective group, not to the total number of patients included in the study.</p>†<p>A p-value ≤0.050 was considered significant.</p>‡<p>In patients with at least one surgical revision of their graft.</p>§<p>Application of negative pressure to the local wound environment using a sealed foam dressing connected to a vacuum pump.</p><p>**Adequate empirical therapy according to the susceptibility testing of the respective isolated pathogen.</p>††<p>Total duration of both empirical and pathogen-specific antimicrobial therapy.</p>‡‡<p>Percentages apply to the total number of patients who were alive at one year within each respective group.</p><p>Comparison of therapies for prosthetic vascular graft infections with respect to the location of the graft.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0112947#nt111" target="_blank">*</a>}</p

Predictors of cure at one year in 51 patients with aortic prosthetic vascular graft infections.^*

<p>HR  =  hazard ratio; CI  =  confidence interval; PVGI  =  prosthetic vascular graft infection.</p><p>*Aortic prosthetic vascular graft infections diagnosed in 51 patients in this single-center study of PVGI over a period of almost 12 years.</p>†<p>Multivariate analysis adjusted for age of patient, location of the aortic graft, graft replacement, presence of a polymicrobial infection, and the use of rifampicin in the antibiotic regimen.</p>‡<p>A p-value ≤0.050 was considered significant.</p>§<p>Each 10-year increment of increase in age is associated with a 0.33 risk of less favorable treatment outcome.</p><p>Predictors of cure at one year in 51 patients with aortic prosthetic vascular graft infections.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0112947#nt119" target="_blank">*</a>}</p

Comparison of primary and secondary outcomes in the treatment of prosthetic vascular graft infection.

<p>PVGI  =  prosthetic vascular graft infection. ^*p-value  = 0.006. ^†p-value  = 0.001. ^‡p-value  = 0.004. ^§p-value  = 0.012. **Removal or replacement of the infected vascular graft. ^††No surgical intervention; antimicrobial treatment only.</p

Comparison of patient characteristics and clinical presentation with respect to graft location in patients with prosthetic vascular graft infection.^*

<p>PVGI  =  prosthetic vascular graft infection; IQR  =  interquartile range; BMI  =  body mass index; COPD  =  chronic obstructive pulmonary disease; ICU  =  intensive care unit; CT  =  computed tomography.</p><p>*Percentages and IQR values indicate relationship to the total number of patients within each respective group, not to the total number of patients included in the study.</p>†<p>A p-value ≤0.050 was considered significant.</p>‡<p>Defined as the total number of patients with a medical history of peripheral arterial occlusive disease, coronary heart disease, or cerebrovascular disease.</p>§<p>Defined as an estimated glomerular filtration rate <60 ml/min/1.73 m² at the time of PVGI diagnosis.</p><p>**There had been no blood cultures drawn for three patients with a thoracic PVGI and for three patients with a peripheral PVGI.</p>††<p>Defined as swabs or biopsies taken from the infected peri-graft areas whose cultures showed microbial growth.</p>‡‡<p>Numbers (%) refer to patients with a specific pathogen isolated; multiple microorganisms per patient were possible. The causative microorganism was identified in blood cultures or in tissue cultures from surgical site for 60 (98.4%) of the 61 patients in the study.</p>§§<p>One out of 14 <i>Staphylococcus aureus</i> isolates was methicillin-resistant.</p><p>Comparison of patient characteristics and clinical presentation with respect to graft location in patients with prosthetic vascular graft infection.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0112947#nt102" target="_blank">*</a>}</p

Comparison of time to treatment failure in different types of prosthetic vascular graft infections.

<p>Infections are compared with respect to the location of the prosthetic vascular graft using Kaplan-Meier estimates.</p

Selection of Patients with <i>Staphylococcus aureus</i> Bloodstream Infection for Final Analysis.

<p>Abbreviations: BSI, bloodstream infection; MELD, Model for End-stage Liver Disease. Sixty-one patients were excluded due to missing medication data on vitamin K antagonists and novel oral anticoagulants.</p

Predictors of 30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection (n <i>=</i> 561); Univariable and Multivariable Analyses.

<p>Predictors of 30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection (n <i>=</i> 561); Univariable and Multivariable Analyses.</p

30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection Stratified by the MELD Score Category at Bloodstream Infection Onset (n = 561).

<p>30-Day All-Cause Mortality in Patients with <i>Staphylococcus aureus</i> Bloodstream Infection Stratified by the MELD Score Category at Bloodstream Infection Onset (n = 561).</p